OTC Switch Pathway Abroad Looks Smoother, But Payoffs Are Lower
This article was originally published in The Tan Sheet
Executive Summary
Switching new Rx drug categories to OTC abroad may appeal to firms put off by the trickle of switches in the U.S., but the payoff abroad is smaller and there is no guarantee FDA will follow another government's decision, experts say
You may also be interested in...
Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says
Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says
Boehringer Launches Switched Flomax Relief MR For BPH In U.K.
Boehringer Ingelheim's U.K. launch of nonprescription Flomax Relief MR for benign prostatic hyperplasia opens a new switch category abroad, but a similar Rx-to-OTC move in the U.S would be more difficult, one expert says